HK Stock Market Move | CSPC PHARMA (01093) surged over 12% after earnings report, with mid-term profit attributable to shareholders increasing by nearly 1.4 times year-on-year.

CSPC PHARMA (01093) rose over 12% after its earnings report, and as of the time of writing, it is up 11.97%, trading at HKD 9.725, with a transaction volume of HKD 3.057 billion. On the news front, on August 20 at noon, CSPC PHARMA announced its mid-term performance for 2026, with total revenue of RMB 18.594 billion, a year-on-year increase of 40.1%; shareholders' reported profit attributable to the company was RMB 6.094 billion, a year-on-year increase of 139.2%; basic earnings per share were 53.45 cents. The company plans to distribute an interim dividend of HKD 0.18 per share. In the first half of 2026, the group obtained a total of 30 IND approvals, with 7 key products approved for market launch, and initiated 18 key Phase III clinical studies. In just the first half of 2026, the group has published 14 research results, including 5 oral presentations, which received positive international feedback and widespread industry attention. Currently, the group has over 200 innovative drugs and formulations under development, including more than 90 macromolecules, over 60 small molecules, and more than 50 novel formulations, many of which have broad market potential and significantly outperform existing therapies in terms of efficacy and safety.